CR6086 + Balstilimab

Rottapharm Biotech is conducting a clinical trial combining balstilimab (PD-1 antagonist) with CR6086 (EP4 antagonist) in patients with pMMR-MSS colorectal cancer. CR6086 is expected to inhibit the immune suppressive role of prostaglandins in the tumor microenvironment, improving immunogenicity and responsiveness to immunotherapy. The Phase 1/2 study commenced in 2021.